GlaxoSmithKline ( (GSK) ) has released its Q1 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
GlaxoSmithKline (GSK) is a global biopharmaceutical company focused on developing innovative medicines and vaccines, with a strong emphasis on specialty medicines and a commitment to responsible business practices.
In its first quarter of 2025, GSK reported a robust financial performance, driven by significant growth in its Specialty Medicines division. The company achieved total sales of £7.5 billion, marking a 4% increase at constant exchange rates, with notable contributions from its HIV, Respiratory, Immunology, Inflammation, and Oncology segments.
Key financial highlights include a 50% increase in total operating profit and a 56% rise in total earnings per share, attributed to lower contingent consideration liabilities and strong sales performance. Specialty Medicines saw a 17% sales growth, while the Vaccines division experienced a 6% decline, primarily due to decreased demand for Shingrix and Arexvy. The company also reported a free cash flow of £0.7 billion and continued its strategic investments in R&D and new product launches.
Looking ahead, GSK remains confident in its 2025 guidance, expecting turnover growth of 3% to 5% and core operating profit growth of 6% to 8%. The company is focused on launching new products and advancing pivotal trials in respiratory, oncology, HIV, and hepatitis, which are expected to drive future growth and shareholder returns.